Slide 1: Q2 2026 Earnings Presentation
Q2 2026 Earnings Earnings Presentation July 29, 2026
Slide 2: Disclaimer
Disclaimer Forward-looking statements Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of Section 27A of To evaluate our performance, we monitor a number of key indicators at the consolidated the Securities Act of 1933 and Section 21E of the Securi
Slide 3: Q2 2026 Overview
Q2 2026 Overview Emmanuel Ligner, President and CEO 3
Slide 4: Key messages
Key messages Revival execution driving financial performance 1 Strategic actions taken over past year starting to improve results Delivered strong Q2 results above expectations, driven by VWR growth 2 VWR returned to organic growth faster than expected Bioscience & Medtech Products (BMP) expected to
Slide 5: Performance highlights – Q2 2026
Performance highlights – Q2 2026 Total Revenue VWR Revenue BMP Revenue $1,692M $1,241M $452M Organic growth Organic growth Organic growth -0.4% +1.7% -5.6% YoY YoY YoY Adj. EBITDA Adj. EPS Free Cash Flow1 $254M $0.21 $152M Growth Growth Adjusted net leverage2 -9.1% -10.5% 3.3x YoY YoY Q2 2026 1. Fre
Slide 6: Revival is delivering results
Revival is delivering results Strategically invest Strengthen our Evolve go to in our manufacturing Optimize our Simplify how talent and improve market strategy and supply chain portfolio we work accountability organization Enhancing Embedding operational Focusing the Streamlining Building a high- c
Slide 7: Revival milestones over the past 12 months
Revival milestones over the past 12 months + Q3’25 Q4’25 Q1’26 Q2’26 • Began comprehensive • Mary Blenn hired as COO • Refreshed ~25% of senior • Ludovic Brellier hired as EVP, operating review after leadership team cumulatively BMP & CTO Emmanuel Ligner joined on • Accelerated digital and e- August
Slide 8: Revival in action: Return VWR to growth
Revival in action: Return VWR to growth + In 2025, we launched a deep review of the business, developed a recovery plan, and began the journey In 2026, we are accelerating capability deployment, execution, and future growth planning Operating Operational VWR Channel Brand and Capability Build Model
Slide 9: Q2 2026 Performance and Capital Allocation
Q2 2026 Performance and Capital Allocation Steve Eck, SVP, Interim CFO and CAO 9
Slide 10: Q2 consolidated performance
Q2 consolidated performance Revenue ($M) Adjusted EPS • Consolidated results ahead of expectations +0.5% $1,683 reported $1,692 $0.24 $0.21 -0.4% -10.5% • VWR returned to organic growth organic • BMP performance near the high end of our expectations Q2'25 Q2'26 Q2'25 Q2'26 • Strong free cash flow Ad
Slide 11: VWR: Q2 2026 segment performance
VWR: Q2 2026 segment performance VWR Distribution & Services • VWR returned to organic growth earlier than anticipated • Growth driven primarily by actions taken to strengthen the franchise • Broad-based momentum across the segment Reported Adjusted • We continue to expect VWR Revenue Operating inco
Slide 12: BMP: Q2 2026 segment performance
BMP: Q2 2026 segment performance Bioscience & Medtech Products • Revenues near high-end of expectations • Solid performance across the segment, with better-than- expected results from Process Chemicals • Double-digit order growth and book-to-bill of 1.1x Reported Adjusted Revenue Operating income •
Slide 13: Robust free cash flow and strengthening balance sheet
Robust free cash flow and strengthening balance sheet Free Cash Flow1 ($M) Q2 2026 Update $187 $150 $152 • Q2 2026 Free Cash Flow of $152M1; reaffirmed FY’26 FCF guidance • Repaid $112M debt in Q2 • Moody’s affirmed credit ratings and revised outlook to positive $39 • Attractive term loan re-pricing
Slide 14: Increased 2026 guidance
Increased 2026 guidance1 FY 2026 guidance FY 2026 guidance Modeling Assumptions (as of April 29, 2026) (as of July 29, 2026) • Reported revenue range is 0.0% to Organic revenue growth -2.5% to -0.5% -0.5% to +0.5% +1.0%, reflecting 0.5% FX tailwind (+1.0% tailwind previously) Adj. EBITDA margin 14.8
Slide 15: Invest with us
Invest with us Executing Revival, our comprehensive program to sharpen focus and improve execution Revival Improving growth Cash generation Our Revival program Returned VWR to Generating strong FCF, is delivering early growth and gaining strategically investing, and results traction in BMP strengthe